MAGL-18c attenuates LPS-induced sepsis-associated liver injury by inhibiting TGF-β/Smad signaling and remodeling medium- and long-chain fatty acid metabolism
These findings indicate that MAGL-18c protects against LPS-induced SALI through coordinated regulation of inflammation, apoptosis, mitochondrial function, and lipid metabolism, highlighting its potential as a promising therapeutic candidate for sepsis-associated liver injury.
Authors
- Miaoxiu Li
- Jiao Xu (ORCID: https://orcid.org/0000-0003-1695-9120)
- Zixia Liang
- Jingchun Yao (ORCID: https://orcid.org/0000-0001-9697-4931)
- Guoxin Dai
- Honghua Li (ORCID: https://orcid.org/0000-0001-6243-3862)
- Guimin Zhang
- Na Guo
- Shirong Li
- Ying Wang
- Xiaoyan Lu
- Yunyu Wang
Institutions
- Qingdao University (CN)
- Tianjin University of Traditional Chinese Medicine (CN)
- Guangdong Pharmaceutical University (CN)
- Pharmaceutical Formulations (United States) (US)
- Luye Pharma (China) (CN)
- Ocean University of China (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-02-05
- DOI
- https://doi.org/10.3389/fimmu.2026.1712807
- Primary Topic
- Sepsis Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00